Abstract
The multidrug resistant protein MDR-1 has been associated with the resistance to a wide range of anti-cancer drugs. Taxol is a substrate for this transporter system and is used in the treatment of a wide range of human malignancies including lung, breast and ovarian cancer. We have generated a series of ovarian cell lines resistant to this compound, all of which overexpress MDR-1 through gene amplification. We present novel evidence that a constitutive activation of the ERK1/2 MAP kinase pathway was also observed although the level of active JNK and p38 remained unchanged. Inhibition of the ERK1/2 MAP kinase pathway using UO126 or PD098059 re-sensitised the Taxol resistant cells at least 20-fold. Importantly, when Mdr-1 cDNA was stably expressed in the wild-type cell line to generate a highly Taxol-resistant sub-line, 1847/MDR5, ERK1/2 MAP kinases again became activated. This result demonstrated that the increased activity of the signalling pathway in the Taxol-resistant lines was directly attributable to MDR-1 overexpression and was not due to the effects of Taxol itself. Additionally, we demonstrated that inhibition of the P13K pathway with LY294002 sensitised the MDR-1-expressing 1847/TX0.5 cells and 1847/MDR5 cells at least 10-fold but had no effect in the wild-type cells. This finding suggests a possible role for this pathway, also, in the generation of resistance to Taxol. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR (1995) PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489–27494
Blagosklonny MV, Chuman Y, Bergan RC and Fojo T (1999) Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 13: 1028–1036
Bosch I and Groop J (1996) P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288: F37–F54
Castro AF, Horton JK, Vanoye CG and Altenberg GA (1999) Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem Pharmacol 58: 1723–1733
Davies SP, Reddy H, Caivano M and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95–105
Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK and Grant S (1998) The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio-and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 12: 1843–1850
Ding S, Yao D, Burchell B, Wolf CR and Friedberg T (1997) High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch Biochem Biophys 348: 403–410
Emanuel SL, Chamberlin HA and Cohen D (1999) Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells. Inter J Oncology 14: 487–494
Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, Reddy EP, Ellmore NW, Galen AT, Lautenberger JA, Papas TS, Westin EH, Wong-Staal F, Gallo RC and Aaronson SA (1982) Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 295: 116–9119
Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA and Trzaskos JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623–18632
Franke TF, Kaplan DR and Cantley LC (1997) P13K: downstream AKTion blocks apoptosis. Cell 88: 435–437
Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D and Murata Y (1999) Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274: 31648–31654
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J and Kohno M (1999) Constitutive activation of the 41/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813–822
Johnstone RW, Cretney E and Smyth MJ (1999) P-Glycoprotein protects leukaemia cells against caspase-dependent, but not caspase-independen, cell death. Blood 93: 1075–1085
Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J and Evan G (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385: 544–548
Keyse SM (1995) An emerging family of dual specificity MAP kinase phosphatases. Biochim Biophys Acta 1265: 152–160
Kim M, So H, Park J, Lee K, Moon B, Lee H, Kim T, Moon S and Park R (2000) Hwansodan protects PC12 cells against serum-deprivation-induced apoptosis via a mechanism involving Ras and mitogen-activated protein (MAP) kinase pathway. Gen. Pharmacol 34: 227–235
Kinloch RA, Treherne JM, Furness LM and Hajimohamadreza I (1999) The pharmacology of apoptosis. Trends Pharmacol Sci 20: 35–42
Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I and Ueda K (1989) P-glycoprotein gene (MDR-1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Comm 162: 224–231
Leevers SJ, Vanhaesebroeck B and Waterfield MD (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 11: 219–225
Ling Y-H, Yang Y, Tornos C, Singh B and Perez-Soler R (1998) Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 58: 3633–3640
MacKeigan JP, Collins TS and Ting JP-Y (2000) MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275: 38953–38956
Mansour SJ, Matten WT, Hermann AS, Candis JM, Rong S, Fukasawa K, Vande Woude GF and Ahn AG (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966–970
Misra S, Ujhazy P, Varticovski L and Arias IM (1999) Phosphoinostide 3-kinase lipid products regulate ATP-dependent transporter by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles. Proc Natl Acad Sci USA 96: 5814–5819
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immuno Methods 65: 55–63
Parekh H, Wiesen K and Simpkins H (1997) Acquisition of Taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 53: 461–470
Plo I, Bettaieb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A, Kowalski-Chauvel A, Laurent G and Lautier D (1999) The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Letters 452: 150–154
Salh BS, Martens J, Hundal RS, Yoganathan N, Charest D, Mui A and Gomez-Munoz A (2000) PD98059 attenuates hydrogen peroxide-induced cell death through inhibition of Jun N-terminal Kinase in HT29 cells. Mol Cell Biol Res Commun 3: 158–165
Sandor V, Fojo T and Bates SE (1998) Future perspectives for the development of P-glycoprotein modulators. Drug Resistance Updates 1: 190–200
Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O and Cabanillas F (1996) Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14: 233–239
Scheid MP and Woodgett JR (2000) Protein kinases: six degrees of separation. Curr Biol 10: R191–R194
Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J and Neckers LM (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16: 5839–5845
Sebolt-Leopold JS, Dudley DT, Herrera R, Becelaere KV, Wiland A, Goman RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR and Saltiel AR (1999) Blockade of the MAP kinase pathway supresses growth of colon tumors. in vivo. Nature Med 5: 810–816
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 21: 99–102
Smith CD and Zilfou JT (1995) Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270: 28145–28152
Smyth MJ, Krasovskis E, Sutton VR and Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95: 7024–7029
Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972
Wang X, Martindale JL, Liu Y and Holbrook NJ (1998) The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 333: 291–300
Wennstrom S and Downward J (1999) Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19: 4279–4288
Wittstein IS, Qiu W, Ziegelstein RC, Hu Q and Kass DA (2000) Opposite effects of pressurized steady versus pulsatile perfusion on vascular endothelial cell cytosolic pH: role of tyrosine kinase and mitogen-activated protein kinase signaling. Circ. Res 86: 1230–1236
Yao M, Shuin T, Misaki H and Kubota Y (1988) Enhanced expression of c-myc and epidermal growth factor receptor (c-erbB-1) genes in primary human renal cancer. Cancer Res 48: 6753–6757
Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV and Cheng JQ (2000) Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19: 2324–2330
Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M, Sers C, Rosenthal A and Schafer R (2000) A genome-wide survey of RAS transformation targets. Nat Genet 24: 144–152
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ding, S., Chamberlain, M., McLaren, A. et al. Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer 85, 1175–1184 (2001). https://doi.org/10.1054/bjoc.2001.2044
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2044
Keywords
This article is cited by
-
A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance
Cell Death & Differentiation (2018)
-
Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152
The Pharmacogenomics Journal (2009)
-
The Multidrug Transporter P-Glycoprotein: A Mediator of Melanoma Invasion?
Journal of Investigative Dermatology (2008)
-
Epithelial-mesenchymal transitions and the expression of twist in MCF-7/ADR, human multidrug-resistant breast cancer cells
Chinese Journal of Clinical Oncology (2007)
-
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1
Oncogene (2006)